Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sangamo Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SGMO
Nasdaq
8731
https://www.sangamo.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sangamo Therapeutics Inc
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
- May 12th, 2024 1:17 pm
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
- May 12th, 2024 12:28 pm
Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)
- May 11th, 2024 1:17 pm
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
- May 10th, 2024 7:58 pm
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
- May 9th, 2024 9:25 pm
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
- May 9th, 2024 8:01 pm
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
- May 9th, 2024 12:05 pm
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
- May 2nd, 2024 9:45 pm
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
- May 2nd, 2024 8:15 pm
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
- Apr 22nd, 2024 8:35 pm
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today
- Mar 25th, 2024 6:52 pm
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
- Mar 22nd, 2024 12:05 pm
Sangamo Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 14th, 2024 1:26 pm
Q4 2023 Sangamo Therapeutics Inc Earnings Call
- Mar 14th, 2024 11:23 am
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Mar 13th, 2024 12:05 pm
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
- Mar 13th, 2024 12:01 pm
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
- Mar 12th, 2024 10:30 pm
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
- Feb 12th, 2024 1:05 pm
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners
- Feb 12th, 2024 1:02 pm
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
- Feb 5th, 2024 11:01 pm
Scroll